Novo Nordisk: acquires Czech site from Novavax
(CercleFinance.com) - US laboratory Novavax announced on Wednesday that it had reached a definitive agreement to sell a Czech Republic-based site to Denmark's Novo Nordisk for $200m.
The asset transfer covers a 14,000 m2 recombinant protein production facility and its adjoining maintenance buildings, as well as the existing workforce and infrastructure.
Novavax justifies its decision by its intention to transform itself into a company with few tangible assets and its desire to invest in its nanoparticle technology platform.
The official sale of the plant is scheduled for 30 December, the transaction's expected completion date.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The asset transfer covers a 14,000 m2 recombinant protein production facility and its adjoining maintenance buildings, as well as the existing workforce and infrastructure.
Novavax justifies its decision by its intention to transform itself into a company with few tangible assets and its desire to invest in its nanoparticle technology platform.
The official sale of the plant is scheduled for 30 December, the transaction's expected completion date.
Copyright (c) 2024 CercleFinance.com. All rights reserved.